CD163 and cancer: A univariate survival analysis indicated that the following clinical factors (P = 0.026) were significantly correlated with a reduction in overall survival: T stage (P < 0.001), N stage (P < 0.001), M stage (P < 0.001), nerve invasion (P = 0.014), cancer embolus (P = 0.039), and CD163 positive macrophage density (P = 0.008).